Maxim analyst Jason McCarthy lowered the firm’s price target on Reviva Pharmaceuticals (RVPH) to $2 from $5 and keeps a Buy rating on the shares, citing dilution for the lowered target following the company’s Q2 update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVPH: